Navigation Links
SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row
Date:7/30/2009

> Snoring Isn't Sexy, LLC boasts membership of 50 dentists with practices in the United States and Canada. In the coming year, Snoring Isn't Sexy, LLC plans to expand its dental membership to 200 dentists globally so that patients in the United States, Canada and other countries will have easy access to well-trained dentists who have received continuing education in the management of sleep breathing disorders.

Snoring Isn't Sexy, LLC was founded in 2008 by Laurence I. Barsh, DMD, a dentist who has been involved with sleep medicine since 1992 and who now devotes full time to educating the public about dentistry's role and responsibility in the recognition and management of snoring and sleep apnea. Dr. Barsh and the dentists associated with Snoring Isn't Sexy, LLC feel strongly that management of sleep-breathing disorders is a shared responsibility of both the medical and dental professions.

Snoring Isn't Sexy, LLC consists of independently owned and operated affiliated offices. Visit www.SnoringIsntSexy.com for a directory of all participating dentists.

Contact:

Laurence I. Barsh, DMD
888.203.0488
315 East 70th St., #7H
New York, NY 10021

###

Read the full story at http://www.prweb.com/releases/sleep_apnea/snoring/prweb2698764.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related medicine news :

1. VAs Suicide Prevention Message Carried on 21,000 Buses
2. New Data Say Uninsured Account for Nearly One-Fifth of Emergency Room Visits
3. VA Advisory Committee on Women Veterans Visits Dallas
4. The Hispanic got milk? Campaign Visits Chicago from July 2 - July 10
5. Finland Biotech Delegation Visits Sundia
6. Study finds virtual doctors visits satisfactory for both patients and clinicians
7. Phish Frontman Trey Anastasio Visits Capitol Hill to Support Drug Courts and Calls on Congress to Put a Drug Court Within Reach of Every American in Need
8. Colgate Bright Smiles, Bright Futures(R) Kids Initiative Visits Los Angeles
9. Colgate Bright Smiles, Bright Futures(R) Kids Initiative Visits Union City, NJ
10. Why parents miss their childrens immunization visits
11. World-renowned neuroscientist visits UTSA on May 5 to discuss the quest for consciousness

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row
SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row
(Date:11/26/2009)...27 With cold and flu season upon u...actices to control the spread of infections and av...ly to keep ourselves healthy, but to avoid transmi... RN, MS, CIC (certified in infection-control), nur...al health at Hospital for Special Surgery (HSS) in...
(Date:11/26/2009)... number of Americans living with diabetes will nea...o 44.1 million in 2034. Over the same period, spen...113 billion to $336 billion, even with no increase...t the University of Chicago report in the December... with diabetes covered by Medicare will rise from ...
(Date:11/26/2009)...oo heavy can lead to strains or worse , ,...be nothing wrong with stuffing your turkey full to...hing with your suitcase as you pack for holiday tr...2008 in U.S. hospital emergency rooms, doctors, of...ggage-related injuries, such as muscle strains, pu...
(Date:11/26/2009)...o more letters from the North Pole, Textsanta.net ...s from Santa , North Pole...al efficiencies at the North Pole Santa Claus has ... over the globe informed of his Christmas progress...earch department have identified a large and growi...
(Date:11/26/2009)...esearch Triangle Dental (RTDental), a leading dent... announced the expansion of its services to includ...oug Macmillan. , Durha...ed to announce that Dr. Doug Macmillan, an experie...ditional advanced training seminar. RTDental&rsqu...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...SAN CARLOS, Calif., Nov. 6 Nektar,Therapeutics (N...ased 32%, or,$100.0 million, of its outstanding co...ollar, for a total purchase price of $47.8 million...argely complete," said Nektar,President and CEO Ho...
...MK-677 brought muscle mass, but long-term effects ...URSDAY, Nov. 6 (HealthDay News) -- An experimenta...owth hormone in seniors to youthful levels, a new ...d to significant improvements in their strength or...
...Third quarter revenues increase 65 percent versus ... at 4:30 p.m. Eastern Time Today, IRVINE, Calif.,...worldwide leader in intravascular temperature,mana...months ended September 30, 2008., Revenue for the...
...Quarterly Revenue Exceeds $10 Million Company Del...tember, BEDFORD, Mass., Nov. 6 Insulet Corporati...nology with its OmniPod(R),Insulin Management Syst...lion compared to,$3.8 million in the third quarter...
..., Atlanta, Ga. November 06, 2008 Down syndrome,...mpairment, occurs in approximately 1-in-700 births...cent of fetuses with Down syndrome are lost before...urrent knowledge of Down syndrome, identify inform...
...STEWARTVILLE, Minn., Nov. 6 Rochester Medical,Cor...g results for its fourth,quarter and year ended Se...les of $9,512,000 for the current quarter,compared...733,000 or $.06 per diluted share for the fourth q...
Other Medicine News:Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 2Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 3Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 4Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 5Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 6Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 7Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 8Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 9Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7Health News:Insulet Reports Third Quarter 2008 Results 2Health News:Insulet Reports Third Quarter 2008 Results 3Health News:Insulet Reports Third Quarter 2008 Results 4Health News:Insulet Reports Third Quarter 2008 Results 5Health News:Insulet Reports Third Quarter 2008 Results 6Health News:Insulet Reports Third Quarter 2008 Results 7Health News:Insulet Reports Third Quarter 2008 Results 8Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8
(Date:11/25/2009)...5 ChemoCentryx, Inc., announced ...pany,s PROTECT-1 (the Prospective Randomized Oral ...aficet-EN(TM) (CCX282-B) in patients with moderate...fficacy with a favorable safety and tolerability p...al efficacy in the reduction of disease severity a...
(Date:11/24/2009)...ewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: EL...or aortic disorders, announced today that it has f...ngs in, the patent infringement lawsuit brought ag... was filed in the United States District Court in ...ed that the stay remain in effect while the United...
(Date:11/24/2009)...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...at the 21st Annual Piper Jaffray Healthcare Confer... (6:00 a.m. PST). The conference is being held at... President and Chief Executive Officer of Anadys, ...l development programs, ANA598 and ANA773. ,, T...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2BEA Opens the Doors to the World at G20 Summit 58230 1BEA Opens the Doors to the World at G20 Summit 58230 2BEA Opens the Doors to the World at G20 Summit 58230 3Market Welby Hosting Free Urgent Care and Medical Practice Fast Growth Marketing Webinar Series 58228 1Market Welby Hosting Free Urgent Care and Medical Practice Fast Growth Marketing Webinar Series 58228 2Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 1Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 2Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 4Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 5
...il 7, 2008 Genta,Incorporated (Nasdaq: GNTA ) an... (oblimersen sodium) Injection, the Company,s lead...l meeting of the American Association,for Cancer R...ego, CA from,April 12-16, 2008. The subject matter...the Company,s ongoing randomized Phase 3 trial of,...
...8 VIA,Pharmaceuticals (Nasdaq: VIAP ), a biotech...unds for the treatment of cardiovascular disease,a...nitoring Board (DSMB),for its VIA-2291 Phase 2 cli... safety for its current Phase 2 studies. The DSMB ...VIA-2291 and recommended VIA,continue its ongoing ...
Other Medicine Technology:Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 2Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 2VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 4
...meter trial lens set has consistently been the mar...g only the highest level of quality throughout the...ns set continues to set the standard for excellenc...o the guidelines established by highly recognized ...
Non-Illuminated Trial Lens Set
Trial Lens Sets
L'Anthony's Desaturated 15 Hue Test
Medicine Products: